Related Experiment Video
Updated: Aug 5, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Early-onset juvenile Paget disease associated with a homozygous intronic TNFRSF11B variant: a 2-year follow-up
Rabia Meral1, Mustafa Gökoğlu2,3
1Department of Pediatric Endocrinology, Necip Fazıl City Hospital, Kahramanmaraş, Türkiye.
Insights
Juvenile Paget disease (JPD) is a rare bone disorder caused by osteoprotegerin (OPG) dysfunction. Early diagnosis and bisphosphonate treatment improved symptoms in an infant, but long-term monitoring is crucial.
Area of Science:
- Pediatric Endocrinology
- Metabolic Bone Disease
- Genetics
Background:
- Juvenile Paget disease (JPD) is an ultra-rare inherited metabolic bone disorder.
- It is characterized by excessive skeletal turnover due to osteoprotegerin (OPG) dysfunction.
- Early diagnosis is critical to prevent severe skeletal and extraskeletal complications in children.
Objectives:
Juvenile Paget disease (JPD) is an ultra-rare inherited metabolic bone disorder characterized by excessive skeletal turnover secondary to osteoprotegerin (OPG) dysfunction. Early diagnosis is important because progressive skeletal and extraskeletal complications may develop during infancy and childhood.
Case Presentation:
We report a 2-month-old infant presenting with severe irritability and pain even with gentle movement, femoral swelling, and persistent hyperphosphatasemia. Skeletal survey demonstrated findings compatible with JPD. Genetic analysis identified a rare homozygous intronic TNFRSF11B variant. Pamidronate treatment resulted in marked biochemical and clinical improvement, including a marked reduction in alkaline phosphatase levels compared with baseline values, resolution of pain, and preservation of neuromotor developmental milestones during the 2-year follow-up period. Cardiovascular evaluation, vascular imaging, and ophthalmologic examinations revealed no abnormalities.
Conclusions:
This case highlights the diagnostic challenges of early-onset JPD and supports the importance of careful clinical, radiologic, and genetic evaluation in infants with persistent hyperphosphatasemia and skeletal abnormalities. Although early bisphosphonate therapy effectively improved skeletal disease activity, extraskeletal manifestations may still occur during follow-up, highlighting the need for continued long-term surveillance.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Sex-linked Disorders
Single Nucleotide Polymorphisms-SNPs
X-linked Traits

